176 related articles for article (PubMed ID: 17078389)
1. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.
Burnett JR
Curr Opin Mol Ther; 2006 Oct; 8(5):461-7. PubMed ID: 17078389
[TBL] [Abstract][Full Text] [Related]
2. Mipomersen.
Am J Cardiovasc Drugs; 2010; 10(4):271-9. PubMed ID: 20653334
[TBL] [Abstract][Full Text] [Related]
3. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
Morse MA
Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
[TBL] [Abstract][Full Text] [Related]
4. ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?
Ito MK
Ann Pharmacother; 2007 Oct; 41(10):1669-78. PubMed ID: 17848425
[TBL] [Abstract][Full Text] [Related]
5. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
Tamm I
Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: ISIS-104838, OraSense.
Kennewell P
Curr Opin Mol Ther; 2003 Feb; 5(1):76-80. PubMed ID: 12669475
[TBL] [Abstract][Full Text] [Related]
7. ISIS-14803 (Isis Pharmaceuticals).
Witherell GW
Curr Opin Investig Drugs; 2001 Nov; 2(11):1523-9. PubMed ID: 11763152
[TBL] [Abstract][Full Text] [Related]
8. Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
Schmitz G
Curr Opin Mol Ther; 2006 Dec; 8(6):547-54. PubMed ID: 17243491
[TBL] [Abstract][Full Text] [Related]
9. Molecule of the Month. Mipomersem sodium.
Drug News Perspect; 2008 Oct; 21(8):464. PubMed ID: 19034352
[No Abstract] [Full Text] [Related]
10. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Bell DA; Hooper AJ; Burnett JR
Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
[TBL] [Abstract][Full Text] [Related]
11. GTI-2040. Lorus Therapeutics.
Orr RM
Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
[TBL] [Abstract][Full Text] [Related]
12. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
Orr RM
Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
[TBL] [Abstract][Full Text] [Related]
13. Technology evaluation: AVI-4126, AVI BioPharma.
Stephens AC
Curr Opin Mol Ther; 2004 Oct; 6(5):551-8. PubMed ID: 15537057
[TBL] [Abstract][Full Text] [Related]
14. Antisense apolipoprotein B therapy: where do we stand?
Akdim F; Stroes ES; Kastelein JJ
Curr Opin Lipidol; 2007 Aug; 18(4):397-400. PubMed ID: 17620855
[TBL] [Abstract][Full Text] [Related]
15. Technology evaluation: ISIS-113715, Isis.
Liu G
Curr Opin Mol Ther; 2004 Jun; 6(3):331-6. PubMed ID: 15264436
[TBL] [Abstract][Full Text] [Related]
16. First oligonucleotide in U.S. clinical trials for CMV retinitis.
AIDS Patient Care STDS; 1997 Jun; 11(3):198-9. PubMed ID: 11361805
[No Abstract] [Full Text] [Related]
17. 128th ENMC International Workshop on 'Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands.
Muntoni F; Bushby K; van Ommen G
Neuromuscul Disord; 2005 Jun; 15(6):450-7. PubMed ID: 15907292
[No Abstract] [Full Text] [Related]
18. Technology evaluation: alicaforsen (Isis).
Gewirtz AT; Sitaraman SV
Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
20. Antisense therapy in the treatment of hypercholesterolemia.
Lippi G; Favaloro EJ
Eur J Intern Med; 2011 Dec; 22(6):541-6. PubMed ID: 22075277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
